Lactoferrin Inhibits Hepatitis C Virus Viremia in Patients with Chronic Hepatitis C: A Pilot Study

Katsuaki Tanaka,1,4 Masanori Ikeda,1,2 Akito Nozaki,1,2 Nobuyuki Kato,2 Hiroyuki Tsuda,3 Satoru Saito1 and Hisahiko Sekihara1

1Third Department of Internal Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 and 2Virology Division, 3Experimental Pathology and Chemotherapy Division, National Cancer Center Research Institute, Tokyo 104-0045

Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.

Key words: Lactoferrin — Chronic hepatitis — Hepatitis C virus
1b in 6 patients, genotype 2a in 4 patients, and genotype 2b in 1 patient. HCV RNA concentrations ranged from 2 to 962 kcopy/ml (mean, 302 kcopy/ml). None had previously received corticosteroid or immunosuppressive treatment. None had a history of alcohol or drug abuse or evidence of metabolic or autoimmune disorders. All patients tested positive for HCV antibodies by enzyme-linked immunosorbent assay (Ortho-HCV ELISA; Ortho Diagnostics, Tokyo). The study was performed according to the guidelines in the Helsinki Declaration. Informed consent was obtained from all patients.

All patients received an 8-week course of lactoferrin treatment. The initial 7 patients received 1.8 g of bovine lactoferrin daily for 8 weeks (total dose: 100.8 g) and the following 4 patients received 3.6 g of bovine lactoferrin daily for 8 weeks (total dose: 201.6 g). Bovine lactoferrin tablets (450 mg) were kindly provided by Morinaga Milk Industry Co. (Tokyo). At the end of lactoferrin treatment, a response to therapy was defined as a decrease of at least 50% in serum ALT and/or HCV RNA concentration compared to the pretreatment value. Serum ALT and HCV viremia were measured immediately before treatment and every 2 weeks thereafter for the next 12 weeks. Serum ALT concentration was determined with a sequential multiple autoanalyzer. Serum HCV RNA concentration was quantitated using an Amplicor HCV Monitor (Nihon Roche, Tokyo). Serum levels of HCV RNA are expressed as copy number per milliliter of serum.

At the end of lactoferrin treatment, a decrease in serum ALT concentration and/or a decrease or absence of serum HCV RNA concentration were apparent in 3 patients (cases 1, 2 and 4); however, the remaining 8 patients (cases 3 and 5 to 11) showed no significant changes in these indices (Table I). Pretreatment serum HCV RNA concentrations of the 3 patients who responded to lactoferrin were less than 100 kcopy/ml. When the response rates were evaluated with regard to the pretreatment HCV RNA concentrations, 3 (75%) of 4 patients whose pretreatment serum HCV RNA concentrations were less than 100 kcopy/ml responded to lactoferrin, while patients whose pretreatment serum HCV RNA concentrations were more than 100 kcopy/ml did not respond to these doses of lactoferrin.

During the follow-up period, 2 (cases 1 and 4) of the 3 patients who responded to lactoferrin relapsed 2 weeks after cessation of the treatment. In case 1, re-treatment with lactoferrin was instituted (Fig. 1). Two weeks after cessation of the initial course of lactoferrin, the serum HCV RNA concentration was markedly elevated (105 kcopy/ml) and serum transaminase levels started to increase (48 U/liter). Four weeks after cessation of lactoferrin, she had an ALT level of 170 U/liter. A second course of lactoferrin (1.8 g/day) was instituted, following which an improvement in serum aminotransferase activities and a decrease in serum HCV RNA concentration were again noted. In case 4, 2 weeks after cessation of the

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yr)/Sex</th>
<th>Histology/*</th>
<th>Genotype</th>
<th>Serum alanine transaminase (U/liter)</th>
<th>Serum HCV RNA concentration (kcopy/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>During treatment (weeks)</td>
<td>After treatment</td>
<td>During treatment (weeks)</td>
<td>After treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Before</td>
<td>2 w</td>
<td>4 w</td>
<td>6 w</td>
</tr>
<tr>
<td>Low pretreatment serum HCV RNA concentration (less than 100 kcopy/ml) group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. 58/female</td>
<td>2A/2a</td>
<td>139</td>
<td>107</td>
<td>70</td>
<td>22</td>
</tr>
<tr>
<td>2. 66/female</td>
<td>2B/2a</td>
<td>56</td>
<td>17</td>
<td>26</td>
<td>24</td>
</tr>
<tr>
<td>3. 51/female</td>
<td>2A/1b</td>
<td>30</td>
<td>43</td>
<td>46</td>
<td>48</td>
</tr>
<tr>
<td>4. 43/male</td>
<td>2B/2a</td>
<td>254</td>
<td>225</td>
<td>243</td>
<td>250</td>
</tr>
<tr>
<td>High pretreatment serum HCV RNA concentration (more than 100 kcopy/ml) group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. 62/male</td>
<td>2B/2b</td>
<td>185</td>
<td>177</td>
<td>160</td>
<td>193</td>
</tr>
<tr>
<td>6. 53/female</td>
<td>2A/1b</td>
<td>96</td>
<td>83</td>
<td>81</td>
<td>78</td>
</tr>
<tr>
<td>7. 49/male</td>
<td>2B/1b</td>
<td>101</td>
<td>97</td>
<td>84</td>
<td>89</td>
</tr>
<tr>
<td>8. 49/female</td>
<td>2B/1b</td>
<td>79</td>
<td>105</td>
<td>82</td>
<td>82</td>
</tr>
<tr>
<td>9. 35/male</td>
<td>2A/2a</td>
<td>32</td>
<td>19</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>10. 50/male</td>
<td>2A/1b</td>
<td>90</td>
<td>72</td>
<td>72</td>
<td>57</td>
</tr>
<tr>
<td>11. 58/female</td>
<td>2B/1b</td>
<td>34</td>
<td>40</td>
<td>31</td>
<td>39</td>
</tr>
</tbody>
</table>

* 2A, chronic active hepatitis 2A; 2B, chronic active hepatitis 2B.
* 3.6 g of bovine lactoferrin administered.
* IFN treatment administered.
* Stronger neo minophagen C administered.
Lactoferrin and Chronic Hepatitis C

In case 1, the serum HCV RNA concentration was elevated (69 kcopy/ml) and IFN treatment was instituted, following which an improvement in serum ami-notransferase activities and a decrease in serum HCV RNA concentration were noted.

No serious complications occurred during or after the treatment. No increases in the serum alkaline phosphatase, lactate dehydrogenase, or total bilirubin levels were observed in any patient. Iron studies were normal in all patients.

Lactoferrin is a multifunctional milk protein associated with many biological activities, including primary nonspecific defense against pathogenic microorganisms. Recently, we found that bovine lactoferrin effectively prevents HCV infection in human PH5CH8 hepatocytes, and demonstrated that the anti-HCV activity of bovine lactoferrin was due to an interaction between bovine lactoferrin and HCV. In this paper, we have demonstrated for the first time that treatment with lactoferrin (1.8 or 3.6 g/day) may be associated with a dramatic decrease in serum HCV RNA concentration and/or a decrease in serum ALT concentration in 3 patients with low pretreatment serum concentrations of HCV RNA. These results strongly suggest that lactoferrin has antiviral activity in patients with chronic HCV infection.

Bovine lactoferrin is thought to reduce serum HCV RNA concentration in hepatitis C patients via the following two distinct mechanisms. The first mechanism, seen in human herpes simplex virus-1, human cytomegalovirus, and human immunodeficiency virus-1 infections, involves the direct interaction of lactoferrin with the cells. However, in rotavirus infection, a second mechanism involves an interaction between lactoferrin and the virus. These results suggest that lactoferrin can bind not only cellular viral receptors, but also viral envelope proteins, to prevent viral infection. More recently, we found that, in the case of HCV, lactoferrin showed no antiviral activity after adsorption and/or internalization of HCV into human PH5CH8 hepatocytes, and that the interaction between lactoferrin and HCV occurred immediately after mixing lactoferrin and serum containing HCV, resulting in the inhibition of adsorption of the HCV-lactoferrin complex into human PH5CH8 hepatocytes (unpublished results). Furthermore, since it has recently been reported that bovine lactoferrin binds to HCV E1 and E2 proteins in vitro, our results suggest that the antiviral activity of bovine lactoferrin is due to the direct binding of bovine lactoferrin to the HCV virion. These results indicate that the anti-HCV activity of lactoferrin is due to a neutralizing activity, which prevents the adsorption of HCV virion into hepatocytes.

We have shown in case 1 that the time course of serum ALT concentration paralleled that of serum HCV RNA during and after the lactoferrin therapy. Furthermore, after cessation of the initial course of lactoferrin, the increase in serum HCV RNA concentration preceded the increase in serum ALT concentration. It has been shown that the reappearance of serum HCV RNA always precedes the

---

![Graph showing the time course of changes in serum alanine transaminase (ALT) and HCV RNA concentrations during bovine lactoferrin (1.8 g/day) treatment in a 58-year-old woman with chronic hepatitis C (case 1).]
increase in serum ALT concentration in patients who relapse.\textsuperscript{22} \textsuperscript{23} Therefore, we believe that the effect of lactoferrin is most likely related to an antiviral mechanism of action.

It has been reported that rats fed a 2\% bovine lactoferrin diet displayed no significant side effects.\textsuperscript{26} Human lactoferrin is especially rich in colostrum, with the maximum concentration estimated to be about 30 mg/ml\textsuperscript{13}; therefore, lactoferrin absorbed by newborns accounts for about 3\% of their total nutrition. Furthermore, an intact form of human lactoferrin of maternal origin has been isolated from the urine of preterm infants fed human milk.\textsuperscript{25} Therefore, the present findings may encourage the clinical use of lactoferrin in patients with C-type chronic hepatitis.

To our knowledge, lactoferrin is the first physiological substance other than IFN found to show anti-HCV activity. Lactoferrin is one potential candidate in the search for an anti-HCV reagent with a low risk of severe clinical side effects. In the present study, we introduced 1.8 g of bovine lactoferrin daily in the initial 7 patients and found that, in patients with high pretreatment serum concentrations of HCV RNA, this dose of lactoferrin was not effective. Therefore, in the following 4 patients, we introduced 3.6 g of bovine lactoferrin daily and found that, in 1 patient (case 10) with high pretreatment serum concentrations of HCV RNA, serum ALT and serum HCV RNA levels dramatically decreased after treatment. The reason for this decrease in these indices after cessation of lactoferrin treatment remains unclear. Since lactoferrin has been shown to be a multifunctional immunoregulatory protein,\textsuperscript{19} high doses of lactoferrin may modulate inflammatory and immune responses. Therefore, in patients with high pretreatment serum concentrations of HCV RNA, a high dose of lactoferrin may be preferable.

In conclusion, this pilot study has shown that lactoferrin is effective in chronic hepatitis patients with low serum concentrations of HCV RNA. Further clinical trials should clarify whether lactoferrin is a potential anti-HCV reagent that will be effective in the treatment of patients with chronic hepatitis.

Dr. Ikeda is the recipient of a Postdoctoral Fellowship from Drug ADR Relief, R&D Promotion and Product Review of Japan. Dr. Nozaki is the recipient of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research, Japan. This work was supported by Grants-in-Aid for Cancer Research and for the 2nd Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan.

\textit{(Received November 13, 1998/Revised March 11, 1999/Accepted March 16, 1999)}

\textbf{REFERENCES}


10) Kato, N., Ikeda, M., Mizutani, T., Sugiyama, K., Noguchi, M., Hirohashi, S. and Shimotohno, K. Replication of hepatic...
Lactoferrin and Chronic Hepatitis C


